| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 1, 2026 | ±2.3% | -4.8% | under-priced |
| November 5, 2025 | ±2.4% | +7.8% | under-priced |
| August 6, 2025 | ±2.1% | -5.1% | under-priced |
| May 2, 2025 | ±2.5% | -0.9% | over-priced |
| October 31, 2024 | ±1.5% | +1.5% | over-priced |
| August 7, 2024 | ±3.0% | -5.0% | under-priced |
| May 3, 2024 | ±2.0% | +11.8% | under-priced |
| October 31, 2023 | ±2.2% | -2.9% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $3.34 | $8.6B | $1.8B |
| Q4 FY2025 | $2.46 | $9.9B | $1.3B |
| Q3 FY2025 | $5.93 | $9.6B | $3.2B |
| Q2 FY2025 | $2.65 | $9.2B | $1.4B |
Amgen Inc (AMGN) reports in 93 days, with the next report estimated for September 14, 2026. Across the last 8 reports, options priced an average ±2.3% earnings move while the stock actually moved 5.0% on average — the market has tended to under-price AMGN's earnings risk. Fundamentals into the print: EPS up 4.4% year-over-year, revenue up 5.8%. QuantLogix's live 5-factor engine currently reads AMGN as a buy at 64/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →